Literature DB >> 2891774

MR/K hemagglutination of Providencia stuartii correlates with adherence to catheters and with persistence in catheter-associated bacteriuria.

H L Mobley1, G R Chippendale, J H Tenney, A R Mayrer, L J Crisp, J L Penner, J W Warren.   

Abstract

Providencia stuartii was the most prevalent bacterial species isolated, for one year, from weekly urine specimens from 51 long-term catheterized patients. Significantly more strains causing bacteriuric episodes of long duration expressed MR/K (mannose-resistant/Klebsiella-like) hemagglutination (74%) than did those causing episodes of short duration (26%; P = .004). Isolates expressing MR/K hemagglutinin bound in higher numbers to catheter material (P = .023) than did those not expressing this hemagglutinin. Significantly more strains causing bacteriuric episodes of short duration expressed the mannose-sensitive (MS) hemagglutinin (43%) than did those causing episodes of long duration (7%; P = .014). Isolates expressing MS hemagglutinin bound significantly more 125I-labeled Tamm-Horsfall protein (THP) than did isolates not expressing this hemagglutinin (P = .0001). Our results indicate that MR/K hemagglutinin plays an important role in the ability of P. stuartii to persist and suggest that MR/K adheres to the catheter. Conversely, MS hemagglutinin binds to THP and may prevent persistence of P. stuartii in the catheterized urinary tract.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2891774     DOI: 10.1093/infdis/157.2.264

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  21 in total

Review 1.  Pathogenesis of Proteus mirabilis Infection.

Authors:  Chelsie E Armbruster; Harry L T Mobley; Melanie M Pearson
Journal:  EcoSal Plus       Date:  2018-02

Review 2.  Potential virulence factors of Proteus bacilli.

Authors:  A Rózalski; Z Sidorczyk; K Kotełko
Journal:  Microbiol Mol Biol Rev       Date:  1997-03       Impact factor: 11.056

3.  Molecular characterization of the type 3 (MR/K) fimbriae of Klebsiella pneumoniae.

Authors:  G F Gerlach; B L Allen; S Clegg
Journal:  J Bacteriol       Date:  1988-08       Impact factor: 3.490

4.  Activities of oral antibiotics on Providencia strains isolated from institutionalized elderly patients with urinary tract infections.

Authors:  G Cornaglia; S Frugoni; A Mazzariol; E Piacentini; A Berlusconi; R Fontana
Journal:  Antimicrob Agents Chemother       Date:  1995-12       Impact factor: 5.191

Review 5.  Complicated catheter-associated urinary tract infections due to Escherichia coli and Proteus mirabilis.

Authors:  S M Jacobsen; D J Stickler; H L T Mobley; M E Shirtliff
Journal:  Clin Microbiol Rev       Date:  2008-01       Impact factor: 26.132

6.  Proteus mirabilis fimbriae: N-terminal amino acid sequence of a major fimbrial subunit and nucleotide sequences of the genes from two strains.

Authors:  F K Bahrani; S Cook; R A Hull; G Massad; H L Mobley
Journal:  Infect Immun       Date:  1993-03       Impact factor: 3.441

Review 7.  Merging mythology and morphology: the multifaceted lifestyle of Proteus mirabilis.

Authors:  Chelsie E Armbruster; Harry L T Mobley
Journal:  Nat Rev Microbiol       Date:  2012-10-08       Impact factor: 60.633

8.  Identification of a conserved chromosomal region encoding Klebsiella pneumoniae type 1 and type 3 fimbriae and assessment of the role of fimbriae in pathogenicity.

Authors:  Carsten Struve; Martin Bojer; Karen Angeliki Krogfelt
Journal:  Infect Immun       Date:  2009-08-24       Impact factor: 3.441

9.  The type 3 fimbrial adhesin gene (mrkD) of Klebsiella species is not conserved among all fimbriate strains.

Authors:  T A Schurtz; D B Hornick; T K Korhonen; S Clegg
Journal:  Infect Immun       Date:  1994-10       Impact factor: 3.441

10.  Fimbriation, capsulation, and iron-scavenging systems of Klebsiella strains associated with human urinary tract infection.

Authors:  A M Tarkkanen; B L Allen; P H Williams; M Kauppi; K Haahtela; A Siitonen; I Orskov; F Orskov; S Clegg; T K Korhonen
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.